| Name | Title | Contact Details |
|---|
Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.
The smart apartment technology that simplifies and empowers from Quext. Automated property management and telecom solutions for multifamily communities.
The Only Place to Shop INSIDE Videos CREATORS | FANS | MERCHANTS #click2cop Sign up now ⬇️ https://t.co/lTQjc9LU7D
Built for fundraisers by fundraisers, our software helps nonprofits manage their donor relationships with a personal touch. Explore our CRM & donor pipeline tools.